Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 2/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404432 | 0.91 | LMNA (0.44) | LMNAKMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL23705084 | 0.90 | TP53 (0.45) | L3MBTL1KLK7KLK5BCHETP53 | |
| SCHEMBL23705152 | 0.90 | TP53 (0.45) | L3MBTL1KLK7KLK5BCHETP53 | |
| SCHEMBL14363001 | 0.87 | SLC6A2 (0.45) | L3MBTL1KLK7KLK5BCHEACACB | |
| SCHEMBL14363002 | 0.86 | L3MBTL1 (0.39) | L3MBTL1KLK7KLK5BCHETP53 | |
| SCHEMBL30040993 | 0.84 | ALDH1A1 (0.47) | LMNAKMT2APOLBALDH1A1TSHR | |
| SCHEMBL26354126 | 0.83 | ALDH1A1 (0.46) | LMNAKMT2APOLBALDH1A1TSHR | |
| SCHEMBL26879052 | 0.81 | TP53 (0.42) | L3MBTL1KLK7KLK5BCHETP53 | |
| SCHEMBL26879054 | 0.81 | TP53 (0.42) | L3MBTL1KLK7KLK5BCHETP53 | |
| SCHEMBL402803 | 0.81 | SLC6A2 (0.43) | L3MBTL1KLK7KLK5BCHEACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | SANOFI-AVENTIS (FR) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270354-A1 | Azasugar derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof | HPSE, HAAO, HEXD | LMNA 3939/4885KMT2A 3760/4885POLB 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.